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Introduction
============

Sepsis is a significant health concern globally with an associated mortality of 14.7% to 29.9% \[[@REF1]\]. Over the years, although the number of sepsis cases and total mortality has increased, the associated case fatality rate has decreased \[[@REF1]\].^ ^Other than the respiratory support with mechanical ventilation, hemodynamic support with fluid resuscitation and vasopressors, and source control of the infection with antibiotics and surgical evacuation of infection, there is no additional approved treatment for either sepsis or septic shock \[[@REF2]\].^ ^Steroids have been evaluated as a treatment option for several years. The suggested theory behind the use of steroids is that they suppress inflammatory mediators and treat sepsis-induced relative adrenal insufficiency, which has been studied in various trials and is yet to be proved \[[@REF3]-[@REF4]\].

A study from 1976 by Schumer et al. showed a significant reduction in mortality in septic shock with high dose steroids given for a short duration \[[@REF5]\].^ ^However, several subsequent studies were unable to replicate these findings but, in turn, showed increased associated mortality due to a higher incidence of superinfection, defined as a new clinical infection that occurred during therapy or within ten days of discontinuation of antimicrobial agents \[[@REF6]-[@REF8]\]. The use of steroids was discouraged until 2002 when the French study by Annane et al. showed significant mortality benefit with the use of steroids, which brought steroids back in favor \[[@REF9]\]. Several subsequent studies, including systematic reviews, meta-analysis, and randomized control trials (RCTs), have not shown consistent evidence for or against steroids in sepsis and septic shock \[[@REF10]-[@REF12]\].^ ^Current surviving sepsis guidelines recommend the use of steroids when fluid resuscitation and vasopressors are not effective in correcting hemodynamic instability, but this remains a weak recommendation \[[@REF2]\]. The two recent RCTs evaluating the use of hydrocortisone in septic shock patients suggested conflicting results leaving clinicians with no explicit guidance \[[@REF13]-[@REF14]\].^ ^There have been no meta-analysis to date which only utilized RCTs for systematic review and meta-analysis. The earlier systematic reviews have used studies, which had a variable patient population with systemic inflammatory response syndrome, sepsis, or septic shock. Those meta-analysis included RCTs, non-randomized trials, observational retrospective, and prospective studies and studies from the 1980s and 1990s where they also used dexamethasone, prednisone, and methylprednisone instead of only potent mineral corticoids, which are hydrocortisone and fludrocortisone. They also included studies in which steroids were used for reasons other than septic shock (e.g., meningitis). Our meta-analysis only incorporates RCTs, which included patients only with septic shock and utilized hydrocortisone alone or with fludrocortisone. Recently published RCTs in The New England Journal of Medicine (NEJM) on March 1, 2018, have not been part of any of the prior systematic reviews and meta-analyses, and the editorial published in the same edition of NEJM recommended to decide about patient management on the basis of subsequent meta-analyses utilizing these two RCTs \[[@REF15]\].

Materials and methods
=====================

We conducted this meta-analysis is to identify the effect of potent mineralocorticoids (hydrocortisone and fludrocortisone) in refractory septic shock patients with possible underlying relative adrenal and mineral corticoid insufficiency and their impact on short-term (defined as 28-day) mortality. The other steroids lack significant mineral corticoid activity as compared to hydrocortisone and fludrocortisone. For the primary outcome, we also performed the sub-group analysis by time to administration of hydrocortisone from time to randomization (early, i.e., within eight hours of randomization vs. late, i.e., within 24-72 hours of randomization). Our secondary outcomes assessed the long-term survival with the intensive care unit (ICU) and the hospital mortality and length of stay (LOS) with reversal of shock. We also evaluated the difference in commonly encountered complications of septic shock, including the incidence of superinfections and limb and cerebral ischemic events.

We completed a systematic review according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) guidelines \[[@REF16]\]. We searched the MEDLINE and PubMed databases from inception until March 01, 2018, only for RCTs, comparing the use of hydrocortisone to the placebo in septic shock patients.

Our search strategy included (glucocorticoid OR hydrocortisone OR steroid) AND (sepsis OR septic OR septic shock). We used the Boolean operator 'OR' to combine the search terms.

Inclusion criteria

1\) Prospective RCTs, 2) Comparing hydrocortisone with or without fludrocortisone to placebos in patients with documented septic shock, 3) Patients age ≥ 18 years, 4) At least 100 patients were randomized in the study, and 5) At least one endpoint was 28-day mortality.

Exclusion criteria

We excluded non-randomized and retrospective studies, studies which used steroids other than hydrocortisone, and total number of patients was \<100; studies that included patients with sepsis and severe sepsis, were in the non-English language, lacked 28-day mortality data, and in which both arms received hydrocortisone.

Primary endpoints

The primary endpoint was mortality at 28 days.

Secondary endpoints

We analyzed the following secondary endpoints: 1) Mortality in ICU; 2) Mortality in the hospital; 3) Mortality at 90 days; 4) Mortality at one year; 5) Reversal of Shock; 6) ICU LOS; 7) Hospital LOS; 8) Incidence of limb and/or cerebral ischemia; and 9) Incidence of superinfection.

Data extraction and quality assessment

Four reviewers, W.J.S., A.R., U.A.S., and M.O.H. extracted the data in the predefined data fields in the Excel sheet for baseline characteristics and study outcomes. They added outcomes that were mentioned in the outcomes tables and described in the text. W.J.S. cross-checked all the entered data and made corrections where necessary. All four reviewers agreed with the corrections and the final entry. Table [1](#TAB1){ref-type="table"} shows the features and differences of individual RCTs, and Table [2](#TAB2){ref-type="table"} summarizes the baseline characteristics of individual trials \[[@REF9],[@REF11]-[@REF14],[@REF17]\]. We used Cochrane collaboration's tool risk assessment of bias in randomized trials for the quality assessment of RCTs \[[@REF18]\] (Figures [1](#FIG1){ref-type="fig"}-[2](#FIG2){ref-type="fig"} and Table [3](#TAB3){ref-type="table"}).

###### Outcomes

  ------------------------------------------------------------- ----------------- -------------------------- ----------- ---------
  Outcome                                                       Effect Estimate   Confidence Interval        p-value     I^2^(%)
  Primary Outcome                                                                                                        
  Mortality at 28 days                                          0.92              0.85 -- 0.99               0.04        0
  Secondary Outcomes                                                                                                     
  Mortality in Intensive Care Unit After sensitivity analysis   0.93 0.87         0.81 - 1.08 0.78 -- 0.97   0.35 0.01   52 0
  Mortality in the hospital                                     0.95              0.84 -- 1.08               0.41        39
  Mortality at 90 days                                          0.93              0.84 -- 1.02               0.13        37
  Mortality at one year                                         0.97              0.84 -- 1.12               0.67        46
  Reversal of Shock                                             1.17              0.74 -- 1.86               0.5         24
  Intensive Care Unit Length of Stay                            0.89              -2.56 to 4.33              0.61        0
  Hospital Length of Stay                                       1.58              -4.23 to 7.38              0.59        0
  The incidence of Superinfection                               1.15              1.04 -- 1.27               0.008       0
  The incidence of limb and/or cerebral ischemia                1.32              0.30 -- 5.90               0.72        0
  ------------------------------------------------------------- ----------------- -------------------------- ----------- ---------

###### Characteristics of Randomized Control Trials

RCT = Randomized Control Trial, F/u = Follow up, n. = number, NEJM = New England Journal of Medicine AJEM: American Journal of Emergency Medicine. JAMA: Journal of the American Medical Association, NZ: New Zealand, KSA: Kingdom of Saudi Arabia, UK: United Kingdom; ICU: Intensive Care Unit, IV = intravenous, w/o = without

  --------------------------------------- ------------------------------------- ---------------------------------------------------------------------- ------------------ --------- --------------------------------- -------------- ----------------------------------------------- --------- ------------------------------------------------- -------------------------------------------------------------------------------------- -------------- -------------------------------------------------------
  Name                                    Design                                Country                                                                Publication Year   Journal   Enrollment                        Population     Time to randomization from the onset of shock   Setting   Intervention Vs. Comparison                       Dose and Type of Steroid and Route of Administration                                   F/u Duration   Average 28-day Mortality across studies n. /total (%)
  2018 APROCCHSS trial \[[@REF14]\]       Double-blind placebo-controlled RCT   France                                                                 3/1/18             NEJM      September 2008- June 2015         Septic shock   Within 24 hours of onset of shock               ICU       Hydrocortisone plus Fludrocortisone vs. Placebo   50 mg IV Q6 hours plus 50 µg 9-α-fludrocortisone via NG tube for 7 days w/o tapering   180 days       451/1271 (35.8)
  2018 ADRENAL trial \[[@REF13]\]         Double-blind placebo-controlled RCT   UK, NZ, KSA, Australia, Denmark                                        1/19/18            NEJM      March 2013- April 2017            Septic shock   Within 24 hours of onset of shock               ICU       Hydrocortisone vs. Placebo                        200 mg/d as a continuous IV Infusion for 7 days                                        90 days        858/3681 (23.3)
  2017 Qing-quan Lv et al. \[[@REF11]\]   Double-blind placebo-controlled RCT   China                                                                  6/4/17             AJEM      September 2015 - September 2016   Septic shock   Within 6 hours of onset of shock                ICU       Hydrocortisone vs. Placebo                        200 mg/d as a continuous IV Infusion for 6 days, then tapered during a 6-day period    28 days        41/120 (34.2)
  2008 CORTICUS trial \[[@REF17]\]        Double-blind placebo-controlled RCT   Austria, Israel, Belgium, UK, Germany, France, Portugal, Netherlands   1/10/08            NEJM      March 2002-November 2005          Septic shock   Within 72 hours of onset of shock               ICU       Hydrocortisone vs. Placebo                        50 mg IV Q6 hours for 5 days; then tapered during a 6-day period                       28 days        164/499 (32.9)
  2002 Annane et al. \[[@REF9]\]          Double-blind placebo-controlled RCT   France                                                                 8/21/02            JAMA      September 1995 - March 1999       Septic shock   Within 8 hours of onset of shock                ICU       Hydrocortisone plus Fludrocortisone vs. Placebo   50 mg IV Q6 hours plus 50 µg 9-α-fludrocortisone via NG tube for 7 days w/o tapering   28 days        173/299 (57.8)
  --------------------------------------- ------------------------------------- ---------------------------------------------------------------------- ------------------ --------- --------------------------------- -------------- ----------------------------------------------- --------- ------------------------------------------------- -------------------------------------------------------------------------------------- -------------- -------------------------------------------------------
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###### Baseline Characteristics of Individuals Trials

no. = Number, SD = Standard Deviation; SAPS = Simplified Acute Physiology Score; SOFA = Sequential Organ Failure Assessment; APACHE = Acute Physiology and Chronic Health Evaluation; SIRS = Systemic Inflammatory Response Syndrome; Pao2:Fio2 = the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen; COPD = Chronic Obstructive Pulmonary Disease; CAD = Coronary Artery Disease; DM = Diabetes Mellitus; CKD = Chronic Kidney Disease; ICU = Intensive Care Unit; IV = Intravenous; N/A = Data not available

  ------------------------------------------------ ----------------------------------- --------------------------------- --------------------------------------- ---------------------------------- -------------------------------- ----------- ---------------- ------------- ---------------------------------- ----------
  Studies                                          2018 APROCCHSS trial \[[@REF14]\]   2018 ADRENAL trial \[[@REF13]\]   2017 Qing-quan Lv et al. \[[@REF11]\]   2008 CORTICUS trial \[[@REF17]\]   2002 Annane et al. \[[@REF9]\]                                                                                 
  Treatment arms                                   Hydrocortisone + Fludrocortisone    Placebo                           Hydrocortisone                          Placebo                            Hydrocortisone                   Placebo     Hydrocortisone   Placebo       Hydrocortisone + Fludrocortisone   Placebo
  N                                                614                                 627                               1853                                    1860                               58                               60          251              248           150                                149
  Male sex --- no. (%)                             402 (65.5)                          424 (67.7)                        1119 (60.4)                             1140 (61.3)                        33 (56.9)                        37 (61.7)   166 (66)         166(67)       96(64)                             104(70)
  Age --- years Mean ± SD                          66±14                               66±15                             62.3±14.9                               62.7±15.2                          68.8±12.6                        64.8±16.7   63±14            63±15         62(15)                             60(17)
  Whites - no. (%)                                 N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         236 (94)         228 (92)      137 (92)                           139 (95)
  Admissions from Medical Ward no. (%)             495 (82.4)                          499 (81)                          1273 (68.8)                             1266 (68.2)                        17 (41.5)                        22 (57.9)   80 (32)          93 (38)       89(59)                             90(60)
  Admissions from Surgery No. (%)                  N/A                                 N/A                               576 (31.2)                              591 (31.8)                         N/A                              N/A         169 (67.8)       153 (62)      61(40.7)                           59(39.6)
  SAPS II                                          56±19                               56±19                             N/A                                     N/A                                N/A                              N/A         49.5±17.8        48.6±16.7     60(19)                             57(19)
  SAPS III                                         N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  APACHE II Score Mean ± SD                        N/A                                 N/A                               24                                      23                                 25.5±9.5                         21.3±6.9    N/A              N/A           N/A                                N/A
  SOFA Score Mean ± SD                             12±3                                11±3                              N/A                                     N/A                                11.9±3.3                         9.9±3.0     10.6±3.4         10.6±3.2      N/A                                N/A
  SIRS Criteria, No. /Total no. (%)                                                                                                                                                                                                                                                                                
  Temperature ≤36 ^o^ C or ≥ 38 ^o^ C              N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Temperature ^o^ C                                N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         37.9±1.5         38.0±1.4      38.0±2                             37.9±2.2
  Heart rate Mean ± SD or \> 90 beats/min          N/A                                 N/A                               96±21.6                                 95±20.9                            N/A                              N/A         119±26           118±25        118±21                             118±21
  Mean arterial pressure --- mm Hg                 N/A                                 N/A                               72.5±8.2                                72.2±8.3                           N/A                              N/A         N/A              N/A           54±10                              55±10
  Systolic Blood Pressure - mm Hg                  N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         94±23            95±27         N/A                                N/A
  Central venous pressure --- mm Hg                N/A                                 N/A                               12.0±5.2                                12.1±5.3                           N/A                              N/A         N/A              N/A           N/A                                N/A
  Lowest mean arterial pressure --- mm Hg          N/A                                 N/A                               57.3±8.5                                57.1±9.1                           N/A                              N/A         N/A              N/A           N/A                                N/A
  Highest lactate level --- mg/dl                  N/A                                 N/A                               34.2±29.1                               34.5±28.2                          N/A                              N/A         3.9±3.6          4.1±4.1       4.6±4.4                            4.3±4.3
  Highest bilirubin level --- mg/dl                N/A                                 N/A                               1.7±2.4                                 1.7±2.4                            N/A                              N/A         N/A              N/A           N/A                                N/A
  Highest creatinine level --- mg/dl               N/A                                 N/A                               2.2±2.0                                 2.1±1.7                            N/A                              N/A         N/A              N/A           N/A                                N/A
  Lowest Pao2:Fio2                                 N/A                                 N/A                               164.6±91.3                              166.4±91.9                         N/A                              N/A         162±89           154±73        176±120                            171±124
  Highest white-cell count --- cells ×10−9/liter   N/A                                 N/A                               17.4±11.4                               17.8±14.7                          N/A                              N/A         N/A              N/A           N/A                                N/A
  Tachypnea, hypocapnia, Mechanical vent           N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Leukocytosis, leukopenia, left shift             N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         14.9±9.8         14.7±9.8      13.1±10.1                          13.0±8.4
  Patients with comorbidities, no. (%)             N/A                                 N/A                               N/A                                     N/A                                54 (93.1)                        49 (81.7)   N/A              N/A           N/A                                N/A
  Hypertension                                     N/A                                 N/A                               N/A                                     N/A                                25 (43.1)                        26 (43.3)   89(35)           98(40)        44(29)                             40(27)
  COPD                                             N/A                                 N/A                               N/A                                     N/A                                2 (3.4)                          4 (6.7)     27(11)           29(12)        17(11)                             24(16)
  CAD                                              N/A                                 N/A                               N/A                                     N/A                                7 (12.1)                         8 (13.3)    37(15)           47(19)        20(13)                             11(7)
  DM                                               N/A                                 N/A                               N/A                                     N/A                                14 (24.1)                        12 (20.0)   51(20)           56(23)        20(13)                             17(11)
  CKD                                              N/A                                 N/A                               N/A                                     N/A                                2 (3.4)                          1 (1.7)     22(9)            21(9)                                             
  Malignancy                                       N/A                                 N/A                               N/A                                     N/A                                9 (15.5)                         13 (21.7)   47(19)           37(15)        23(15)                             18(12)
  Community Acquired Infection                     468 (77.7)                          459 (75.5)                        N/A                                     N/A                                N/A                              N/A         N/A              N/A           94(63)                             93(62)
  Nosocomial, ICU                                  N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Nosocomial, Ward                                 N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Nosocomial                                       N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           30(20)                             34(23)
  Site of Infection no. (%)                                                                                                                                                                                                                                                                                        
  Unknown                                          11 (1.8)                            18 (2.9)                          145 (7.9)                               136 (7.3)                          7 (12.1)                         4 (6.1)     N/A              N/A           2(1)                               0
  Lung                                             373 (60.7)                          363 (58)                          623 (33.8)                              677 (36.5)                         22 (37.9)                        22 (36.7)   N/A              N/A           61(41)                             70(47)
  Abdomen                                          74 (12.1)                           68 (10.9)                         477 (25.9)                              467 (25.2)                         21 (36.2)                        34 (56.7)   N/A              N/A           26(17)                             23(15)
  Urinary Tract                                    102 (16.6)                          118 (18.8)                        146 (146 (7.9)                          133 (7.2)                          10 (17.2)                        7 (11.7)    N/A              N/A           7(5)                               7(5)
  Skin and soft tissues                            N/A                                 N/A                               137 (7.4)                               116 (6.3)                          2 (3.4)                          1 (1.7)     N/A              N/A           8(5)                               12(8)
  Bacteremia                                       N/A                                 N/A                               N/A                                     N/A                                18 (31.0)                        13 (21.7)   N/A              N/A           39(26)                             31(21)
  Surgical wound                                   N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Positive blood culture no. (%)                   225 (36.6)                          229 (36.6)                        316 (1.1)                               325 (17.5)                         42 (72.4)                        44 (73.3)   N/A              N/A           39(26)                             31(21)
  Documented pathogen no. (%)                      450 (73.3)                          441 (70.4)                        N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Gram-positive bacteria no. (%)                   235 (38.3)                          228 (36.4)                        N/A                                     N/A                                4 (6.9)                          4 (6.7)     N/A              N/A           46 (31)                            37 (25)
  Gram-negative bacteria no. (%)                   261 (42.5)                          264 (42.2)                        N/A                                     N/A                                26 (44.9)                        31 (51.7)   N/A              N/A           37 (25)                            45 (30)
  Adequate antimicrobial therapy no. (%)           595 (96.9)                          595 (96.2)                        1817 (98.3)                             1821 (98.1)                        48 (82.8)                        47 (78.3)   N/A              N/A           137 (91)                           141 (95)
  Vasopressor administration                                                                                                                                                                                                                                                                                       
  Epinephrine                                                                                                                                                                                                                                                                                                       
  No. of patients                                  53                                  58                                134                                     113                                N/A                              N/A         35(14)           22(9)         41                                 31
  Dose --- μg/kg/min                               2.31±6.62                           1.74±2.41                         N/A                                     N/A                                N/A                              N/A         0.6±1.2          0.9±2.6       0.8±0.7                            1±0.9
  Norepinephrine                                                                                                                                                                                                                                                                                                   
  No. of patients                                  534                                 554                               1823                                    1821                               N/A                              N/A         224(89)          231(93)       46                                 48
  Dose --- μg/kg/min                               1.02±1.61                           1.14±1.66                         N/A                                     N/A                                1.7±2.1                          1.2±1.4     0.5±0.6          0.4±0.5       1.1±1.1                            1.0±1.1
  Glucocorticoids                                                                                                                                                                                                                                                                                                  
  IV No./Total No. (%)                             N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Hydrocortisone equivalent, (range), mg           N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Etomidate                                                                                                                                                                                                                                                                                                         
  No. / Total no. (%)                              N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         22/251(8.6)      20/248(8.1)   N/A                                N/A
  Mean (SD), mg                                    N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Mechanical ventilation no. (%)                   567 (92.3)                          569 (91.3)                        1845 (99.8)                             1855 (99.9)                        52 (89.7)                        51 (85.0)   228(91)          212(86)       87(58)                             75(50.3)
  Renal-replacement therapy no. (%)                161 (27)                            168 (28.1)                        228 (12.3)                              242 (13.0)                         24 (41.4)                        18 (30.0)   N/A              N/A           N/A                                N/A
  Organ failure n. (%)                             N/A                                 N/A                               N/A                                     N/A                                10 (17.2)                        6 (10.0)    N/A              N/A           N/A                                N/A
  Respiratory                                      N/A                                 N/A                               N/A                                     N/A                                7 (12.1)                         4 (6.7)     N/A              N/A           N/A                                N/A
  Liver                                            N/A                                 N/A                               N/A                                     N/A                                1 (1.7)                          1 (1.7)     N/A              N/A           N/A                                N/A
  Renal                                            N/A                                 N/A                               N/A                                     N/A                                3 (5.2)                          1 (1.7)     N/A              N/A           N/A                                N/A
  Coagulation                                      N/A                                 N/A                               N/A                                     N/A                                3 (5.2)                          1 (1.7)     N/A              N/A           N/A                                N/A
  Microcirculatory                                 N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  Central nervous system                           N/A                                 N/A                               N/A                                     N/A                                N/A                              N/A         N/A              N/A           N/A                                N/A
  ------------------------------------------------ ----------------------------------- --------------------------------- --------------------------------------- ---------------------------------- -------------------------------- ----------- ---------------- ------------- ---------------------------------- ----------

Data synthesis and analysis

Statistical Method 

We used a random effects model for our statistical analysis in RevMan Version 5.3 Copenhagen. We used the Mantel-Haenszel method for the statistical analysis of dichotomous data to calculate the risks ratio and inverse variance for the continuous data to estimate the mean difference. We reported our results using the effect estimate with 95% confidence interval. A two-sided p-value of ≤ 0.05 was considered statistically significant.

Heterogeneity

We used I2 and Chi2 statistics to estimate the heterogeneity with RevMan Version 5.3 Copenhagen. Variability between studies (inter-study) compared to variability within studies (intra-study) was assessed with the I2 statistic; I2 \>50% indicates substantial heterogeneity as mentioned in the Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0, Part 2: General Methods for Cochrane Reviews \[[@REF19]\]. We performed a sensitivity analysis for substantial heterogeneity.

Study Selection

We identified 244 citations for RCTs. Two reviewers W.J.S. and P.I. reviewed the abstracts of each study and selected 25 articles and reviewed their full papers. They excluded 20 papers and selected five articles for qualitative and quantitative analysis comparing hydrocortisone to the placebo in patients with septic shock. Figure [1](#FIG1){ref-type="fig"} shows the PRISMA study flow diagram and Table [4](#TAB4){ref-type="table"} summarizes the excluded studies failing to meet the inclusion criteria.

###### Cochrane Risk of Bias for Quality Assessment

  --------------------------------------- ------------------------------------------------------------------------------------------ ------------------------ ---------------------------------------- -------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------
  Name                                    Random Sequence                                                                            Allocation Concealment   Blinding of Participants and Personnel   Blinding of Outcome Assessment   Incomplete Outcome Data                                                                                 Selective Reporting
  2018 APROCCHSS trial \[[@REF14]\]       Yes Via Centralized Randomization Web site, stratified using permutation blocks Low Risk   Yes Low Risk             Yes Low Risk                             Yes Low Risk                     No Low Risk                                                                                             No Low Risk
  2018 ADRENAL trial \[[@REF13]\]         Yes Password-protected, encrypted, Web-based Interface Low Risk                            Yes Low Risk             Yes Low Risk                             Yes Low Risk                     No Low Risk                                                                                             No Low Risk
  2017 Qing-quan Lv et al. \[[@REF11]\]   Yes Computer-generated random numbers Low Risk                                             Not Reported Unclear     Yes Low Risk                             Not Reported Unclear             No Low Risk                                                                                             No Low Risk
  2008 CORTICUS trial \[[@REF17]\]        Yes Computerized random-number generator Low Risk                                          Yes Low Risk             Yes Low Risk                             Yes Low Risk                     Yes High Risk                                                                                           No Low Risk
  2002 Annane et al. \[[@REF9]\]          Yes Computer-generated random number Low Risk                                              Yes Low Risk             Yes Low Risk                             Yes Low Risk                     Yes One person withdrew consent after getting assigned treatment was excluded from analysis High Risk   No Low Risk
  --------------------------------------- ------------------------------------------------------------------------------------------ ------------------------ ---------------------------------------- -------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------

*Qualitative Analysis* 

We included five RCTs with 5,838 patients in our analysis. 2,914 patients were randomized to the hydrocortisone arm vs. 2,924 to the placebo arm. Two studies used Fludrocortisone in addition to hydrocortisone in the steroid arm \[[@REF9],[@REF14]\]. (Table [5](#TAB5){ref-type="table"})

###### Summary of Studies Excluded

  -------------------- ------------------------ ------------------------------------------------------- ---------------------------- ------------------------------------------------ ------------------------------ ------------------------------------------------------- -------------------------------------------- -----------------
  Total Studies        Studies Included         Studies Excluded                                                                                                                                                                                                                                                          
  244                  5                        239                                                                                                                                                                                                                                                                        
  Exclusion Criteria   Non-Randomized Studies   Steroids Other Than Hydrocortisone or Fludrocortisone   N of studies less than 100   Studies either not of steroids or Septic Shock   Non-English Language Studies   No reporting of Primary Outcome i.e. 28-day mortality   Studies which were Study Designs/Protocols   Age \< 18 years
  n\.                  8                        8                                                       4                            199                                              1                              4                                                       4                                            11
  -------------------- ------------------------ ------------------------------------------------------- ---------------------------- ------------------------------------------------ ------------------------------ ------------------------------------------------------- -------------------------------------------- -----------------

Results
=======

Primary endpoints

See Table [1](#TAB1){ref-type="table"}.

Mortality at 28 Days

There was a total of 1,688 deaths with a significantly reduced number of deaths in the hydrocortisone and fludrocortisone arm as compared to the placebo arm. There were 808 deaths in the hydrocortisone arm vs. 880 in the placebo arm, risk ratio (RR) = 0.92, confidence interval (CI) = 0.85 - 0.99, p = 0.04, I2 = 0 %, suggesting the mortality benefit at 28 days with hydrocortisone and fludrocortisone in septic shock patients. The sub-group analysis of the early administration of hydrocortisone, i.e., within eight hours of randomization showed no difference between the two groups, 105 in hydrocortisone group vs. 110 in the placebo arm, RR = 0.98, CI = 0.73 - 1.32, p = 0.90, I2 = 38%. The sub-group analysis of the late administration of hydrocortisone, i.e., within 24-72 hours of randomization showed a non-significant trend towards decreased mortality in the hydrocortisone arm, 703 vs. 770 in the placebo arm, RR = 0.92, CI = 0.83 - 1.01, p = 0.09, I2 = 16% (Figure [2](#FIG2){ref-type="fig"}).

Secondary endpoints

See Table [1](#TAB1){ref-type="table"}.

Mortality in the ICU

There was a total of 856 deaths in the ICU with no difference in the number of deaths between the two groups, the hydrocortisone arm (409) vs. the placebo arm (447), RR = 0.93, CI = 0.81-1.08, p = 0.35, I2 = 52% (Figure [3](#FIG3){ref-type="fig"}). There was substantial heterogeneity between the two groups. On running the sensitivity analysis without the results of the Corticosteroid Therapy of Septic Shock (CORTICUS) trial, the results became statistically significant favoring hydrocortisone and fludrocortisone with I2 reducing to 0%. Hydrocortisone arm = 307 vs. placebo arm = 358 RR = 0.87, CI = 0.78-0.97, p = 0.01, I2 = 0%.

![Risk of Bias Graph](cureus-0011-00000004914-i03){#FIG3}

Mortality in the Hospital

There were a total of 974 deaths during the hospital stay with no difference in either arm, 468 in the hydrocortisone arm vs. 506 in the placebo arm, RR = 0.95, CI = 0.84 - 1.08, p = 0.41, I2 = 39% (Figure [4](#FIG4){ref-type="fig"}).
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Mortality at 90 Days

Two trials reported 90-day mortality. There was a non-significant trend towards decreased mortality at 90 days in the hydrocortisone and fludrocortisone group, 775 vs. 834 in the placebo arm, RR = 0.93, CI = 0.84-1.02, p = 0.13, I2 = 37% (Figure [5](#FIG5){ref-type="fig"}).
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Mortality at One Year

Two studies reported one-year mortality. There was no difference in mortality between the two groups at one year, 239 deaths in each arm, RR = 0.97, CI = 0.84-1.12, p = 0.67, I2 = 46% (Figure [6](#FIG6){ref-type="fig"}).
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Reversal of Shock

Two studies reported the shock reversal outcome. A total of 238 patients in the hydrocortisone group had shock reversal as compared to 226 in the placebo arm. There was no statistical difference between the two groups, OR = 1.17, CI = 0.74-1.86, p = 0.50, I2 = 24% (Figure [7](#FIG7){ref-type="fig"}).
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ICU LOS

Only two studies reported the ICU LOS. There was no difference in the LOS in the ICU between the two groups, point estimate = 0.89 days, CI = -2.56 to 4.33, p = 0.61, I² = 0% (Figure [8](#FIG8){ref-type="fig"}).
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Hospital LOS

Two studies reported the LOS in the hospital. No statistical difference was observed in the two arms, point estimate = 1.58 days, CI = -4.23 to 7.38, p = 0.59, I² = 0% (Figure [9](#FIG9){ref-type="fig"}).
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Incidence of Limb and/or Cerebral Ischemia

Two studies reported the incidence of either limb and/or cerebral ischemia. There was no difference in the two groups, four in the hydrocortisone arm as compared to three in the placebo arm, RR = 1.32, CI = 0.30-5.9, p = 0.72, I² = 0% (Figure [10](#FIG10){ref-type="fig"}).
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Incidence of Superinfection

Three studies reported the incidence of superinfection in the two treatment arms. Hydrocortisone was associated with a significantly higher number of superinfections as compared to placebo, 436 vs. 385, RR = 1.15, CI = 1.04-1.27, p = 0.008, I² = 0% (Figures [11](#FIG11){ref-type="fig"}-[13](#FIG13){ref-type="fig"}).
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![Forest Plot Showing the Incidence of Limb and/or Cerebral Ischemia](cureus-0011-00000004914-i12){#FIG12}
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Discussion
==========

The use of steroids in septic shock patients remains controversial due to the inconsistent results of previous trials and meta-analyses. Some authors believe that the significant variation in results could be due to dosing, duration of administration, and timing of initiation of steroids \[[@REF20]-[@REF21]\]. In pre-1997 trials, steroids were used in higher doses for a shorter duration. Subsequent studies were done after 1997 used steroids in physiological doses but for a longer duration, i.e., seven days. In the landmark study by Annane et al., steroids were started within three to eight hours after the diagnosis of septic shock, which led to a significant reduction in mortality \[[@REF9]\]. However, in the CORTICUS trial, steroids were started within 12 hours of diagnosis, and no mortality benefit was observed \[[@REF17]\]. Nonetheless, both of these trials showed an early reversal of shock in the steroid group. Due to the controversies surrounding the timing of steroid use noted in previous studies, Qing-Quan Lv et al. initiated steroids at the same time when vasopressors were started and found that reversal of shock was similar in both groups and there was no mortality difference either \[[@REF11]\]. In the two recent landmark trials, ADRENAL (Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock) and APROCCHSS (Activated Protein C and Corticosteroids for Human Septic Shock), steroids were started four and six hours after the initiation of vasopressors. Both trials also showed a reduction in pressor requirement with the use of steroids. Another point of debate has been regarding continuous infusion versus intermittent bolus dosing. The HYPRESS (Hydrocortisone for Prevention of Septic Shock) trial, which randomized patients with severe sepsis before developing septic shock, studied the continuous infusion of hydrocortisone with a taper over six days. It also failed to uncover any significant mortality benefit nor did it prevent the development of septic shock \[[@REF12]\]. However, the surviving sepsis campaign guidelines recommend only intermittent bolus doses of hydrocortisone and not continuous infusion \[[@REF2]\].

Amidst all this confusion, recently, two large multicenter RCTs were published to confirm or refute the findings of previous studies. In the ADRENAL trial, nearly 3,800 patients were randomized and assigned to receive a continuous infusion of either hydrocortisone or placebo. This study was adequately powered to determine a mortality difference \[[@REF13]\]. In the APROCCHSS trial, a total of 1,241 patients were randomized to receive either a hydrocortisone - fludrocortisone combination or placebo \[[@REF14]\]. The primary outcome in both trials was mortality at 90 days. The ADRENAL trial showed no significant mortality benefit at 90 days; on the other hand, in the APROCCHSS trial, a mortality benefit was noted in the hydrocortisone and fludrocortisone group. Both trials did show an early reversal of shock and rapid cessation of mechanical ventilation, which was similar to the results of earlier studies \[[@REF9],[@REF17]\].

A review of these trials provides some additional insights into the subsets of patients who might benefit from the addition of corticosteroid therapy on top of conventional treatment for sepsis. The RCT with lower overall mortality (HYPRESS) had no mortality benefit, likely due to less sick patients (severe sepsis vs. septic shock) \[[@REF12]\], and the trials with the highest mortality (French, APROCHSS) likely with the sickest patients, showed a mortality benefit \[[@REF9],[@REF14]\]. This suggests that the addition of steroids may be helpful in patients who are "sicker," and, in this case, unresponsive to conventional therapy of fluids, vasopressors, and antibiotics. Additionally, in the ADRENAL trial, there was a mortality benefit in the sub-group that received steroids after the first six hours, before which the patient, otherwise responsive to conventional goal-directed therapy, would be "selected out," leaving patients who may have an additional benefit from corticosteroid therapy. Similarly, our sub-group analysis of the primary outcome on the basis of time to administration of hydrocortisone from randomization suggested a strong trend towards reduced mortality in the late administration group as compared to the early administration group (within eight hours vs. within 24 to 72 hours). Since the trials in the late administration group may also have patients who received hydrocortisone within eight hours of randomization could have led to a non-significant trend towards decreased mortality. These observations would remain speculative in the absence of a randomized trial looking at these specific outcomes and warrant a randomized clinical trial looking at hydrocortisone use in patients who are unresponsive to early goal-directed therapy. Such a trial would indeed be challenging to design and implement, given logistic and ethical issues.

Our study noted a statistically significant mortality benefit of the primary outcome of mortality at 28 days in the hydrocortisone group as compared to placebo. Also, there was a non-significant reduction in ICU mortality in the hydrocortisone arm, which became statistically significant after sensitivity analysis. This finding also suggests that the use of hydrocortisone incurs a mortality benefit in the ICU setting in addition to 28 days. However, the rates of superinfection were noted to be higher in the hydrocortisone group as compared to the placebo, which is consistent with the results of individual trials and older studies. The strength of our analysis primarily lies in study selection. We included only RCTs, which included patients with a septic shock, which compared hydrocortisone to placebo, and studies with at least a hundred patients in the trial. This is in contrast to earlier meta-analyses, which also included non-RCTs, cohort and retrospective studies, and studies with small population sizes with different steroids, including methyl-prednisolone, dexamethasone, betamethasone, hydrocortisone, and prednisone \[[@REF10],[@REF20]\].

The limitations in performing this meta-analysis are: we included trials ranging from 2002 up until now. The management of sepsis and septic shock has evolved since early 2000, and so have the surviving sepsis guidelines \[[@REF2],[@REF22]-[@REF25]\], which is evident by the reduction in mortality from 57.8% in the French study \[[@REF9]\] to 23.3% to 35.8% in subsequent studies \[[@REF11],[@REF13]-[@REF14],[@REF17]\]. Two out of five trials included fludrocortisone in addition to hydrocortisone. The recommendations from the American College of Critical Care Medicine and the surviving sepsis campaign in 2008 have reported that hydrocortisone has enough mineralocorticoid effects, making the administration of fludrocortisone irrelevant. Thus, we believe that the addition of fludrocortisone could not have provided a significant benefit to influence the results of our study \[[@REF22],[@REF25]\]. The last limitation was the way steroids were administered in individual RCTs, bolus vs. continuous infusion.

Conclusions
===========

Our analysis showed a significant reduction in mortality at 28 days and a non-significant trend in ICU mortality and mortality at 90 days in the hydrocortisone group. The rates of superinfection were noted to be significantly higher in the hydrocortisone group. We believe there is still controversy over hydrocortisone, and we don't know which patients, if any, should receive the drug. In the future, large RCTs are required before any new recommendations can be made comparing hydrocortisone to placebo, hydrocortisone plus fludrocortisone to placebo, and hydrocortisone to hydrocortisone plus fludrocortisone. Another potential trial can be designed comparing the time from the development of septic shock to the administration of hydrocortisone.
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